Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus

Kaposi’s Sarcoma (KS) is a neoplasm derived from endothelial cells and is associated with human herpesvirus-8 (HHV-8) infection. It is mostly seen in patients suffering from AIDS and/or chronic immunosuppression. Currently, systemic chemotherapy is the primary treatment option for the advanced KS. However, there is no consensus on the treatment of KS. In this case, an 84-year-old man with a history of psoriasis developed multiple painful dark purple nodules on the trunk and extremities during the treatment of drug reaction with eosinophilia and systemic symptoms (DRESS). KS was confirmed by the skin biopsy, and the immunohistochemical staining demonstrated the positivity for HHV-8 while the anti-HIV test was negative. The patient then received anlotinib treatment, a tyrosine kinase inhibitor, for 5 months, and his skin lesions subsided. This case indicates that anlotinib may be a potential treatment option for KS.

[1]  Wei Sun,et al.  Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study , 2022, Clinical Medicine Insights. Oncology.

[2]  G. Bao,et al.  Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study , 2021, BMC Cancer.

[3]  Ben Ma,et al.  The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-arm Phase II Clinical Trial. , 2021, Thyroid : official journal of the American Thyroid Association.

[4]  Shenglong Li Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma , 2021, Frontiers in Oncology.

[5]  A. Perrone,et al.  Electrochemotherapy in Kaposi sarcoma: A systematic review. , 2021, Molecular and clinical oncology.

[6]  İ. Aral,et al.  Palliative treatment of Kaposi sarcoma with radiotherapy: a single center experience , 2021, Radiation oncology journal.

[7]  Y. Sun,et al.  [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma]. , 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[8]  T. Shiohara,et al.  Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[9]  I. Zalaudek,et al.  Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). , 2019, European journal of cancer.

[10]  S. Steinberg,et al.  A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma , 2019, Clinical Cancer Research.

[11]  Z. Duan,et al.  Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma , 2019, International journal of cancer.

[12]  M. Rudek,et al.  Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Pantanowitz,et al.  Kaposi sarcoma. , 2013, Archives of pathology & laboratory medicine.

[14]  K. Tkaczuk,et al.  Update on taxane development: new analogs and new formulations , 2012, Drug design, development and therapy.

[15]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[16]  M. Lagunoff,et al.  KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes , 2012, Front. Microbio..

[17]  A. Tourlaki,et al.  Intralesional vincristine as first‐line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients , 2009, The British journal of dermatology.

[18]  Anthony Marmarou,et al.  Diagnosis and management of idiopathic normal-pressure hydrocephalus: a prospective study in 151 patients. , 2005, Journal of neurosurgery.

[19]  Kaposi,et al.  Idiopathisches multiples Pigmentsarkom der Haut , 1872, Archiv für Dermatologie und Syphilis.

[20]  D. Donnell,et al.  Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi’s Sarcoma , 2001, American journal of clinical dermatology.